Elimination of N-glycosylation by site mutation further prolongs the half-life of IFN-α/Fc fusion proteins expressed in Pichia pastoris
         by Hao Jia et al.
Jia et al. Microb Cell Fact  (2016) 15:209 
DOI 10.1186/s12934-016-0601-9
RESEARCH
Elimination of N-glycosylation by site 
mutation further prolongs the half-life  
of IFN-α/Fc fusion proteins expressed in Pichia 
pastoris
Hao Jia1,2†, Yugang Guo1,2,3*†, Xiaoping Song1,4, Changsheng Shao2,3, Jing Wu1,2,3, Jiajia Ma1,2,3, Mingyang Shi1,2, 
Yuhui Miao1,2, Rui Li1,2, Dong Wang1,2, Zhigang Tian1,2,3 and Weihua Xiao1,2,3*
Abstract 
Background: Interferon (IFN)-α has been commonly used as an antiviral drug worldwide; however, its short half-life 
in circulation due to its low molecular weight and sensitivity to proteases impacts its efficacy and patient compliance.
Results: In this study, we present an IgG1 Fc fusion strategy to improve the circulation half-life of IFN-α. Three differ-
ent forms of IgG1 Fc fragments, including the wild type, aglycosylated homodimer and aglycosylated single chain, 
were each fused with IFN-α and designated as IFN-α/Fc-WT, IFN-α/Fc-MD, and IFN-α/Fc-SC, respectively. The recombi-
nant proteins were expressed in Pichia pastoris and tested using antiviral and pharmacokinetic assays in comparison 
with the commercial pegylated-IFN-α (PEG-IFN-α). The in vitro study demonstrated that IFN-α/Fc-SC has the highest 
antiviral activity, while IFN-α/Fc-WT and IFN-α/Fc-MD exhibited antiviral activities comparable to that of PEG-IFN-α. 
The in vivo pharmacokinetic assay showed that both IFN-α/Fc-WT and IFN-α/Fc-MD have a longer half-life than PEG-
IFN-α in SD rats, but IFN-α/Fc-SC has the shortest half-life among them. Importantly, the circulating half-life of 68.3 h 
for IFN-α/Fc-MD was significantly longer than those of 38.2 h for IFN-α/Fc-WT and 22.2 h for PEG-IFN-α.
Conclusions: The results demonstrate that the elimination of N-glycosylation by mutation of putative N-glycosyla-
tion site further prolongs the half-life of the IFN-α/Fc fusion protein and could present an alternative strategy for 
extending the half-life of low-molecular-weight proteins expressed by P. pastoris for in vivo studies as well as for future 
clinical applications.
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Background
Interferon (IFN)-α belongs to a class of cytokines that 
play an important role in host defenses due to their 
potent antiviral, immunomodulatory, and anti-prolif-
erative activities [1]. IFN-α is commonly used to treat 
chronic hepatitis B and C virus (HBV and HCV) infec-
tions and certain cancers [2, 3]. The conventional IFN-α 
with a small molecular size of approximately 18 kDa has a 
short half-life of approximately 2–3 h because of its high 
sensitivity to serum proteolytic enzymes and rapid clear-
ance by the kidneys [4]. Thus, patients must experience 
frequent injections and fluctuations in plasma drug con-
centration, which are associated with common adverse 
events such as fever, headache, and chill, especially in 
long-term treatment. To overcome this problem, two 
pegylated versions of IFN-α have been introduced with 
an extended half-life of 35–77 h in patients and a reduced 
injection frequency of once weekly [1]. Moreover, human 
albumin-fused IFN-α, called Albuferon, has a longer half-
life of up to 120 h, which would allow for administration 
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once every 2–4 weeks. Unfortunately, Albuferon has not 
yet been approved because of safety concerns at high 
doses [5]. Several forms of human IgG Fc-fused IFN-α 
fusion proteins expressed in mammalian cell lines have 
produced promising results in preclinical studies [2, 
5, 6]. In fact, more than ten therapeutic Fc fusion pro-
teins have been approved for clinical use by the FDA, 
and some of these proteins have achieved great success 
on the market, such as Enbrel (TNFR-Fc) [7]. Moreover, 
three ‘biobetters’ of Fc fusion proteins, including Eloctate 
(Factor VIII-Fc), were approved by the FDA in 2014 [7]. 
These successful cases greatly inspire our confidence in 
the use of Fc fusion proteins to extend the serum half-life 
of IFN-α.
There is a specific asparagine-linked glycosylation site 
(297 N) in each Fc region of heavy chains of IgG1 [8], and 
the absence of glycosylation at 297 N of Fc is not required 
for neonatal FcRn binding [9]. Thus, the glycosylation 
site could be mutated to eliminate N-glycosylation in Fc 
when expressed in the yeast Pichia pastoris, an expres-
sion system commonly used to control the cost of pro-
duction [10]. Moreover, it is reported that monomeric 
Fc binds to human FcRn at a rate comparable to that of 
normal Fc [11], and IFN-α appears to biologically func-
tion as a monomer [12]. Thus, in this study, three differ-
ent IFN-α/Fc fusion proteins, including IFN-α fused to 
the wild-type IgG1 Fc fragment (IFN-α/Fc-WT), IFN-α 
fused to a modified IgG1 Fc fragment (IFN-α/Fc-MD) 
and IFN-α fused to a modified single-chain IgG1 Fc 
fragment (IFN-α/Fc-SC), were designed and expressed. 
To evaluate the in vitro properties and the antiviral and 
anti-proliferative activities of IFN-α/Fc fusion proteins, 
conventional IFN-α and pegylated IFN-α (PEG-IFN-α, 
Pegasys) were compared in several cell lines. To evalu-
ate the in vivo properties of the fusion proteins, a phar-
macokinetic study was conducted in rats. The objective 
of this study was to provide one or two possible forms of 
IFN-α/Fc fusion proteins for further applications.
Methods
Strains, plasmids, antibodies and equipment
Pichia pastoris strain GS115, Escherichia coli strain 
DH5α, and expression vector pPIC9 were purchased 
from Invitrogen (Life Technologies). MDBK and Daudi 
cells were obtained from Wuhan Boster. The plasmid 
pPIC9K-Kex-IFNα2b-Fcγ1 with the coding gene of fused 
human IFN-α2b and the wild-type human IgG1 Fc frag-
ment was constructed and preserved in our laboratory 
[13]. WISH cells, the conventional IFN-α and the anti-
IFN-α monoclonal antibody were obtained from Anke 
Biotechnology Group. HPR-conjugated anti-mouse 
antibodies were purchased from Cell Signaling. The 
14-L fermenter (New Brunswick BioFlo115) used in 
pilot-scale fermentation was obtained from Eppendorf. 
A flex stand system with 0.45-μm hollow fiber mem-
brane filtration cartridges and an AKTA Avant system 
with MabSelect and S-200 HR columns were obtained 
from GE Healthcare.
Molecular design and cloning
The fusion protein IFN-α/Fc-WT was secreted into 
culture medium as the active form of disulfide-linked 
homodimer with a single N-glycosylation modification in 
the IgG1 Fc region in each molecule. Overlap extension 
PCR was used for site-specific mutagenesis of the glyco-
sylation site on the IgG1 Fc fragment and for the inser-
tion of a flexible GS linker between the C-terminus of 
IFN-α and the N-terminus of the IgG1 Fc fragment.
The primer pairs (see Additional file 1: Table S1) α-Fw 
and SC-Rv, SC-Fw and M-Rv, and M-Fw and Fc-Rv were 
used to amplify three parts of the fused coding sequence 
of the IFN-α/Fc-SC monomer on the template plasmid 
pPIC9K-Kex-IFNα2b-Fcγ1 (pIFN-α/Fc-WT), which was 
used for expression of the fusion protein IFN-α/Fc-WT. 
The PCR procedure was as follows: 94  °C for 5  min; 32 
cycles of 94 °C for 30 s, 55 °C for 40 s, and 72 °C for 60 s; 
and 72  °C for 10  min. The primer pair α-Fw and Fc-Rv 
was used to splice the three amplified parts to obtain the 
complete fused IFN-α2b and the IgG1 gene. The PCR 
procedure was as follows: 94  °C for 5  min; 32 cycles of 
94  °C for 30  s, 55  °C for 40  s, and 72  °C for 120  s; and 
72  °C for 10 min. This newly amplified gene encoding a 
single-chain IFN-α2b and the IgG1 Fc fragment-fused 
protein contained a mutated glycosylation site on the 
IgG1 Fc fragment (297 N to Q) with the insertion of a GS 
linker between IFN-α2b and the IgG1 Fc fragment. The 
amplified gene was digested with the restriction enzymes 
BamH  I and EcoR  I and was inserted into the same 
digested pPIC9 vector. This recombinant expression vec-
tor is denoted as pIFN-α/Fc-SC.
The primer pairs α-Fw and MD-Rv and MD-Fw and 
Fc-Rv were used to amplify two parts of the fused coding 
sequences of the IFN-α/Fc-MD homodimer on the tem-
plate plasmid pIFN-α/Fc-SC. The PCR procedure was as 
follows: 94 °C for 5 min; 32 cycles of 94 °C for 30 s, 55 °C 
for 40  s, and 72  °C for 60  s; and 72  °C for 10  min. The 
primer pair α-Fw and Fc-Rv was used to splice the two 
amplified parts to obtain the complete fused IFN-α2b and 
the IgG1 gene. The PCR procedure was as follows: 94 °C 
for 5 min; 32 cycles of 94 °C for 30 s, 55 °C for 40 s, and 
72 °C for 120 s; and 72 °C for 10 min. This newly ampli-
fied gene encoding a homo-dimerized IFN-α2b and the 
IgG1 Fc fragment-fused protein also contained a mutated 
glycosylation site on the IgG1 Fc fragment with the inser-
tion of a protein linker between IFN-α2b and the IgG1 
Fc fragment. This newly amplified gene was digested 
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with the restriction enzymes BamH  I and EcoR  I and 
was inserted into the same digested pPIC9 vector. This 
recombinant expression vector was denoted as pIFN-α/
Fc-MD.
Screening for expression
The recombinant expression vectors pIFN-α/Fc-WT, 
pIFN-α/Fc-MD and pIFN-α/Fc-SC were linearized by 
the restriction enzyme Sal I. The linearized vectors were 
transformed into P. pastoris strain GS115. The positive 
transformants were screened by MD plates and examined 
by Western blot using anti-human IgG-HRP conjugates 
according to a previous report [14].
Fermentation and purification
The fed-batch fermentation process was performed in a 
14 L fermentor (NBS BioFlo 115) with 6 L BMGY media 
containing 4% glycerol according to previous reports 
with necessary modifications [15]. Specifically, the cul-
ture temperature was maintained at 25  °C, and the pH 
was controlled at 6.0 with ammonium hydroxide. More-
over, after induction by 100% methanol supplemented 
with 12 mL/L of PTM1 solution, the DO was set to about 
30% air saturation and fermentation was allowed to pro-
ceed for less than 18 h to reduce degradation of the tar-
geted products. At the end of fermentation, the pH of the 
fermentation broth was adjusted to 8.0 by 5  M NaOH 
and then centrifuged for 20  min at 10,000  g. After cen-
trifugation, the supernatant was filtered through 0.45-μm 
hollow fiber membranes using the FlexStand benchtop 
system. A HiTrap MabSelect affinity chromatography 
column was used to capture the recombinant IFN-α/
Fc-fused proteins from the clarified supernatants. The 
captured proteins were further purified with HiPrep 
Sephacryl S-200 HR size-exclusion chromatography and 
stored at −80 °C.
Characterization of the fusion proteins
SDS-PAGE under reduced and non-reduced conditions 
was performed to analyze the purified proteins. Approxi-
mately 10 μg of each IFN-α/Fc fusion protein was loaded 
and separated by 10% SDS-PAGE; the gel was stained 
with Coomassie brilliant blue. Western blotting was also 
performed using the anti-IFN-α monoclonal antibody 
or anti-human IgG-HRP conjugates. The protein sam-
ples were separated by 10% SDS-PAGE under reduced 
conditions and then transferred to a PVDF membrane 
for 30 min at 18 V. The membrane was blocked with 5% 
skim milk for 1 h and then incubated with the indicated 
antibodies. The membrane was washed three times with 
TBST and then incubated with anti-mouse HRP-conju-
gated secondary antibodies. The protein was detected 
using a chemiluminescence detection kit after the mem-
brane was washed three times with TBST. A Periodic 
acid-Schiff (PAS) staining kit (Catalog No. DG0005, 
Beijing Leagene Biotechnology) was used according 
to the manufacturer’s instructions to characterize the 
glycosylated modification of the fusion proteins. The 
recombinant proteins were also analyzed by liquid chro-
matography–mass spectrometry (LC–MS), which was 
performed as previously described [16].
Antiviral activity assay
WISH or MDBK cells were diluted with DMEM con-
taining 10% fetal bovine serum (FBS) to 2.5  ×  105–
3.5  ×  105  cells/mL. Each well of a 96-well plate was 
seeded with 100 μL of these diluted cells. Approximately 
6 h later, the medium was replaced with DMEM contain-
ing 7% FBS and serially diluted samples. After 24 h, the 
medium was replaced with DMEM containing 3% FBS 
and 100 TCID50 VSV. Another 24 h later, the cell viability 
was measured using an MTT assay. The activities of dif-
ferent samples were calculated using Origin 8 software. 
The experiments were run in triplicate.
Anti‑proliferation assay
Daudi cells were diluted with DMEM containing 10% 
FBS to 5  ×  105  cells/mL. Each well of a 96-well plate 
was seeded with 50 μL of the diluted cells. Then, 50 μL 
of DMEM containing 10% FBS was added, and the sam-
ples were serially diluted. After 72 h, the cell viability was 
measured using the MTT assay. The EC50 values of differ-
ent samples were calculated using Origin 8 software. The 
experiments were run in triplicate.
2′, 5′‑oligoadenylate synthetase (OAS) mRNA assay
Human PBMCs were isolated from the peripheral blood 
of healthy adult volunteers using Ficoll density gradient 
centrifugation and diluted with RPMI 1640 medium con-
taining 10% FBS to 1.5 ×  105–2.0 ×  105  cells/mL. Each 
well of a 6-microwell plate was seeded with 2 mL of the 
diluted cells. After 12 h of incubation, the indicated sam-
ples were added to each well at a final concentration of 
10 ng/mL. After 20 h of incubation, the total RNA of the 
cultured cells was isolated with TRIzol extraction. Real-
time quantitative RT-PCR was used to detect the expres-
sion of the targeted genes according to a previous report 
[1].
Pharmacokinetics study
Fifteen Sprague–Dawley (SD) rats with weights ranging 
from 180 to 220  g were randomly and equally divided 
into five groups. A 20% ethyl carbamate solution at a 
dose of 5  mL/kg was used for animal anesthesia. After 
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anesthesia, the indicated samples were injected intrave-
nously into corresponding animal groups with a single 
30 μg/kg dose. Blood samples of the treated group were 
collected prior to dosing and at the following times after 
dosing: 0.2, 8, 24, 48, 72, 96, 120 and 144  h. Heparin 
sodium was used for anticoagulation, and then the blood 
samples were centrifuged for plasma harvest. The inter-
feron levels of the blood samples were analyzed using 
cytometric bead array (CBA) according to the manufac-
turer’s instructions. The pharmacokinetic parameters 
were calculated using the software PKsolver with a non-
compartmental model [17].
Statistical analysis
Difference between groups was analyzed by applying 
the one-way analysis of variance (ANOVA) with Tukey’s 
test (P < 0.05 as significant, P < 0.01 as highly significant, 
P < 0.001 as very highly significant).
Results
Molecular design of IFN‑α/Fc fusion proteins
In this study, all three genes were under the control of 
the classical alcohol oxidase 1 (AOX1) promoter, and 
their expression was induced by methanol in P. pastoris. 
Schematic diagrams of the fusion proteins are shown 
in Fig.  1. Compared to IFN-α/Fc-WT, the glycosylation 
site on the IgG1 Fc fragment was mutated (297 N to Q), 
and a flexible GS linker replaced the partial hinge (eight 
amino acids of the N-terminus of the hinge) of IgG1 Fc in 
IFN-α/Fc-MD. IFN-α/Fc-SC became a monomeric fusion 
protein via replacement of the full hinge region with the 
GS linker.
Expression of IFN‑α/Fc fusion proteins
The three recombinant expression vectors IFN-α/Fc-WT, 
IFN-α/Fc-MD and IFN-α/Fc-SC were each transformed 
into P. pastoris strain GS115. The process and results of 
transforming, screening and expressing were similar for 
each IFN-α/Fc fusion protein. For example, the positive 
transformants were first screened by dot blot (Fig.  2a), 
and then, the selected high-expression clones were fur-
ther confirmed by Western blot (Fig.  2b). One of these 
high-expression strains was used in pilot-scale fermenta-
tion. As shown in Fig. 2c, the IFN-α/Fc-MD fusion pro-
tein began to accumulate after induction by methanol 
in fermentation. This induction was allowed to proceed 
for less than 18 h to prevent degradation of the targeted 
products.
Purification and characterization of IFN‑α/Fc fusion 
proteins
After fermentation, the recombinant proteins were cap-
tured using HiTrap MabSelect affinity chromatography, 
which is specifically used for the purification of Fc fusion 
protein or antibodies. HiPrep Sephacryl S-200 size exclu-
sion chromatography was used for polishing purification. 
The purity of the recombinant proteins was greater than 
Fig. 1 Schematic diagram for IFN-α/Fc fusion proteins. The dimer is 
composed of two molecules of IFN-α joined to dimeric Fc, and the 
monomer has a single molecule of IFN-α linked to monomeric Fc. 
Black circles N-glycosylation site in the wild-type IgG1 Fc region; DB 
disulfide bridges between dimeric Fc; F-hinge full hinge region of 
IgG1; P-hinge partial hinge with the amino acid sequence of HTCPPCP
Fig. 2 Expression of the IFN-α/Fc-MD fusion protein. The transformed 
colonies of IFN-α/Fc-MD were screened by dot blot (a); and further 
confirmed by Western blot (b). a1–c8: the colony number. c The time 
period for the expression of IFN-α/Fc-MD during induction in fermen-
tation was analyzed by Western blot under reduced and non-reduced 
conditions
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90% when examined by SDS-PAGE, as shown in Fig. 3a. 
In addition, the predicted molecular weight (MW) of 
IFN-α/Fc-WT, IFN-α/Fc-MD and IFN-α/Fc-SC is 90.8, 
90.0 and 44.4  kDa, respectively. The apparent MW of 
IFN-α/Fc-SC under non-reduced conditions was approx-
imately half that of IFN-α/Fc-WT and IFN-α/Fc-MD, but 
under reduced conditions, the apparent MW was close to 
that of IFN-α/Fc-WT and IFN-α/Fc-MD, indicating that 
IFN-α/Fc-SC is a monomeric fusion protein. Western 
blot was performed to demonstrate that both IFN-α and 
the antibody Fc fragment were present in the fusion pro-
teins, as shown in Fig. 3b. The fusion proteins were also 
confirmed by subsequent LC-MS peptide mapping (data 
not shown). PAS staining and Coomassie brilliant blue 
staining of the same SDS-PAGE gel collectively showed 
that site-specific mutagenesis of the N-glycosylation site 
in the Fc region can dramatically reduce the glycosylation 
level of the fusion proteins (Fig. 3c).
Anti‑viral activity of IFN‑α/Fc fusion proteins
Two common in  vitro test systems were used to evalu-
ate the anti-viral activity of the IFN-α/Fc fusion proteins. 
In the WISH-VSV system, conventional IFN-α exhibited 
the significantly higher anti-viral activity, comparing 
with the three IFN-α/Fc-fused proteins and PEG-IFN-α 
(P  <  0.001), and three IFN-α/Fc-fused proteins showed 
similar anti-viral activity compared to PEG-IFN-α 
(Fig. 4a). At 106.82 IU/mg, the anti-viral activity of IFN-α/
Fc-SC was slightly higher than that of IFN-α/Fc-WT, 
IFN-α/Fc-MD and PEG-IFN-α, but this difference did 
not reach statistical significance (P > 0.05). In the MDBK-
VSV system (Fig.  4b), similarly, conventional IFN-α 
still exhibited the significantly higher anti-viral activ-
ity comparing with the three IFN-α/Fc-fused proteins 
and PEG-IFN-α (P  <  0.001) and IFN-α/Fc-SC showed 
the higher anti-viral activity than IFN-α/Fc-WT and 
IFN-α/Fc-MD but the difference was still not significant 
(P > 0.05). Human PBMCs were treated with 10 ng/mL of 
the indicated samples. The total RNA was extracted, and 
real-time quantitative RT-PCR was used to evaluate the 
transcription levels of OAS1 and STAT1 (Table 1). With 
respect to the OAS1 transcription level, three IFN-α/Fc 
fusion proteins in this study showed similar activities, 
which were less than that of PEG-IFN-α. There was no 
dramatic difference in the transcription of STAT1 among 
the IFN-α/Fc fusion proteins and PEG-IFN-α. 
Anti‑proliferation activity of IFN‑α/Fc fusion proteins
Daudi cells were used to evaluate the anti-proliferation 
activity of the IFN-α/Fc fusion proteins. The anti-prolif-
eration activities of the three IFN-α/Fc-fused proteins in 
this study were comparable to that of PEG-IFN-α (Fig. 5). 
Similar to the anti-viral activity, the anti-proliferative 
activity of IFN-α/Fc-SC was also slightly higher than 
those of IFN-α/Fc-WT and IFN-α/Fc-MD, but the differ-
ence did not reach statistical significance (P > 0.05).
Pharmacokinetics study
The plasma concentration data were analyzed using a 
non-compartmental model, and the results are shown 
in Fig. 6. The half-life of IFN-α/Fc-MD was 68.3 h, much 
longer than that of the other samples, including PEG-
IFN-α, whose half-life was 20.2  h (P  <  0.001). The half-
life of IFN-α/Fc-MD was approximately twice as long as 
that of IFN-α/Fc-WT. This result shows that eliminating 
N-glycosylation by site mutation in the IgG1 Fc region 
can significantly enhance the half-life of IFN-α/Fc fusion 
Fig. 3 Characterization of purified IFN-α/Fc fusion proteins. a 
Comparison of purified IFN-α/Fc fusion proteins using SDS-PAGE 
under reduced and non-reduced conditions. b Western blot analysis 
of the purified IFN-α/Fc fusion proteins. The indicated samples were 
separated via reduced SDS-PAGE and identified through Western blot 
analysis with goat anti-human IgG-HRP conjugate or mouse anti-
human IFN-α monoclonal antibodies, followed by rabbit anti-mouse 
IgG-HRP conjugate. c PAS staining of purified IFN-α/Fc fusion proteins 
via SDS-PAGE under reduced conditions. WT: IFN-α/Fc-WT, MD: IFN-α/
Fc-MD, SC: IFN-α/Fc-SC, M: prestained protein marker
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proteins. The half-life of IFN-α/Fc-SC was 18.6 h, shorter 
than that of the other two fusion proteins and PEG-
IFN-α but still much longer than that of conventional 
IFN-α, whose half-life was too short to be detected at 8 h 
post-administration.
Discussion
Although the two forms of pegylated IFN-α produced 
by pharmaceutical companies are listed as first-line anti-
viral drugs for chronic hepatitis B treatment by AASLD 
and EASL [18], for most patients with chronic hepatitis 
Fig. 4 Antiviral activity of IFN-α/Fc fusion proteins. The protective effects of IFN-α/Fc fusion proteins and two controls (recombinant human IFN-α 
and pegylated interferon PEG-IFN-α) at the indicated concentrations were evaluated in antiviral assays using human WISH (a) and bovine MDBK (b) 
challenged with the VSV virus. All data are presented here as mean ± standard deviation of the OD values
Table 1 Induction of  mRNA expression by  IFN-α/Fc fusion 
proteins in PBMCs
PBMCs were treated with 10 ng/mL of indicated samples. RNA was extracted 
and the level of induction was measured relative to untreated cells (PBS) by 
quantitative PCR









Fig. 5 Anti-proliferative activity of IFN-α/Fc fusion proteins. Daudi 
cells were incubated for 72 h in the presence of increasing concen-
trations of the indicated samples with triple parallel wells in 96-well 
plates. Cell proliferation was assessed using the MTT method. All data 
are presented here as mean ± standard deviation of the OD values
Fig. 6 Pharmacokinetics of IFN-α/Fc fusion proteins. SD rats (n = 3 
per group) were intravenously administered a single dose of 30 µg/kg 
of the indicated samples via the vena caudalis. Blood samples were 
drawn prior to treatment and at 0.2, 8, 24, 48, 72, 96, 120 and 144 h 
after the treatment. The serum human IFN-α level was quantified 
using the CBA Human IFN-α Flex Set. All data are presented here as 
mean ± standard deviation of the concentrations
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B, especially for those in China, Pegasys or PegIntron 
are too expensive. Consequently, patients must choose 
conventional IFN-α with affordable prices. Thus, it is 
urgent to develop an alternative IFN-α with an excel-
lent pharmacokinetic performance and at a low cost 
for developing countries. In this study, three forms of 
active IFN-α/Fc fusion proteins were designed and suc-
cessfully expressed in the P. pastoris expression system, 
which provides industrial potential for producing solu-
ble, secreted and functional recombinant proteins with 
post-translational modifications at a low cost [19]. It is 
noted that the fermentation process needs further opti-
mization to improve expression levels. In this study, fer-
mentation was only performed in routine condition to 
collect enough proteins for this study, It is worth enough 
to making much effort to optimize the fermentation con-
ditions, including optimizations of culture medium, pH, 
temperature, strategies of methanol feeding and so on 
[10, 19].
The three forms of IFN-α/Fc fusion proteins and two 
controls were tested for anti-viral and anti-cell prolifera-
tion activity using different in  vitro test systems. Inhib-
iting the cytopathic effect of VSV infection in human 
(WISH) and bovine (MDBK) cell lines presents two clas-
sical methods for studying the anti-viral activity of IFNs 
[1, 20]. As expected, conventional IFN-α had the highest 
anti-viral activity of approximately 108.9 IU/mg in both 
systems in our study, which is consistent with previous 
publications in which test systems were varied within 
a reasonable range [1, 5, 6]. All three IFN-α/Fc fusion 
proteins exhibited activities comparable to that of PEG-
IFN-α. The activity of IFN-α/Fc-SC was slightly higher 
than those of IFN-α/Fc-WT and IFN-α/Fc-MD due to 
apparent steric hindrance between the IFN-α moiety and 
the Fc fragment [6]. IFN-α/Fc-SC may have more flex-
ibility to facilitate binding to the corresponding receptors 
of IFN-α. It is noted that the IFN-α/Fc-SC in this study 
is a single-chain form of the IFN-α/Fc fusion protein, 
which is different from the previous monomeric IFN-α/
Fc composed of one IFN-α molecule and the dimeric Fc 
domain of human IgG1 in another study [6]. Compare to 
the monomeric IFN-α/Fc in previous study [6], the puri-
fication process of IFN-α/Fc-SC could be much simpler 
because IFN-α/Fc-SC is a single molecule that can not 
form unwanted dimmers as found in the monomeric 
IFN-α/Fc [6]. Obviously, the production cost of IFN-α/
Fc-SC in this study is much lower than that of the mono-
meric IFN-α/Fc with a heterodimeric structure. Moreo-
ver, the antiviral activity could be further improved by 
optimizing the linker length between IFN-α and Fc [2, 6]. 
OAS1 plays an important role in IFN-α-dependent anti-
viral immunity [1]. The ex vivo transcription level of the 
OAS1 gene after interferon stimulation was examined. 
Consistent with the in vitro WISH-VSV and MDBK-VSV 
study, all IFN-α/Fc fusion proteins exhibited activities 
comparable to that of PEG-IFN-α.
IFN-α also functions in antitumor activity in mouse 
and human malignancies and has been approved as 
an antineoplastic therapeutic drug in clinical practice 
for more than 30 years [3]. The Daudi cell is a human B 
lymphoblast cell line that is highly sensitive to the anti-
proliferative effects of IFN-α and is commonly used as 
an in  vitro test system to evaluate the anti-proliferation 
activity of all types of recombinant IFN-α [1]. Similar to 
the anti-viral results presented above, there were compa-
rable activities among the three IFN-α/Fc fusion proteins 
and PEG-IFN-α.
The pharmacokinetic study in SD rats showed that 
the three forms of IFN-α/Fc fusion proteins had a sig-
nificantly increased half-life compared to that of con-
ventional IFN-α, whose half-life was only approximately 
0.5  h in rats [21] and rapidly decreased to undetect-
able levels by 8 h post-administration in this study. The 
half-lives of IFN-α/Fc-WT and IFN-α/Fc-MD were 38.2 
and 68.3  h, respectively. These proteins showed a supe-
rior potency compared to PEG-IFN-α, with a half-life 
of 20.2 h in our study, consistent with other studies [21, 
22]. Thus, both IFN-α/Fc-WT and IFN-α/Fc-MD possess 
advantages over commercial PEG-IFN-α regarding half-
life elongation. Moreover, the half-life of IFN-α/Fc-MD 
was much longer than that of IFN-α/Fc-WT.
The N-glycosylation of recombinant proteins has been 
thought to have a significant impact on the pharma-
cokinetics of glycosylated therapeutics [23]. The post-
translational glycosylation modification is usually high 
mannose type (mostly Man9–Man12) in wild-type P. 
pastoris [19, 24]. The IFN-α/Fc-WT was likely processed 
by N-glycosylated modification when expressed in P. pas-
toris (Fig.  3c). It has also been reported that the serum 
clearance of glycoproteins through the mannose recep-
tor is one of the major pathways for selective glycopro-
tein clearance from circulation [23]. It is also reported 
that glycosylated mAbs with terminal high mannose 
glycans exhibited fast clearance from the blood [25]. 
High mannose-type glycosylation may reduce the half-
life of IFN-α/Fc-WT expressed in P. pastoris through a 
mannose receptor on most immune cells, such as mac-
rophages, endothelial cells and immature DCs, resulting 
in protease degradation instead of FcRn receptor degra-
dation in those macrophages that recycle proteins [26, 
27]. To confirm the above hypothesis, mannose receptor 
knockout mice could be used to further investigate the 
pharmacokinetics of IFN-α/Fc-WT and IFN-α/Fc-MD in 
the future [28, 29].
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Conclusions
In this study, elimination of N-glycosylation of IFN-α/
Fc-MD by site mutation confers a much longer half-
life compared to IFN-α/Fc-WT and presents another 
alternative strategy for enhancing the half-life of glyco-
sylated proteins in P. pastoris. This study supports the 
strategy that the production of aglycosylated forms of 
some therapeutic Fc-fusion proteins in P. pastoris is a 
feasible approach when facing high cost in mammalian 
cells. Finally, this study also suggests that IFN-α/Fc-MD 
or IFN-α/Fc-SC could be a reasonable form of IFN-α/Fc 
fusion protein expressed in P. pastoris for use in further 
research and applications.
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